Tango Therapeutics, Inc. (TNGX) is a publicly traded company in the Unknown sector. Across all available filings, 20 corporate insiders have executed 82 transactions totaling $80.8M, demonstrating a bearish sentiment with -$37.5M in net insider flow. The most recent transaction on Jan 8, 2026 involved a transaction of 1,650,000 shares valued at $0.
No significant insider buying has been recorded for TNGX in the recent period.
No significant insider selling has been recorded for TNGX in the recent period.
Based on recent SEC filings, insider sentiment for TNGX is bearish with an Insider Alignment Score of 27/100 and a net flow of -$37.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Tango Therapeutics, Inc. (TNGX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 20 insiders are actively trading TNGX stock, having executed 82 transactions in the past 90 days. The most active insider is Rock Ventures Gp Iv, L.p. Third (Executive), who has made 10 transactions totaling $24.2M.
Get notified when executives and directors at TNGX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Peters Malte | Executive | Award | 1,650,000 | $N/A | $0 | |
| Jan 8, 2026 | Peters Malte | Executive | Award | 350,000 | $N/A | $0 | |
| Jan 2, 2026 | Lee Sung | Executive | Award | 60,000 | $N/A | $0 | |
| Jan 2, 2026 | Lee Sung | Executive | Award | 10,000 | $N/A | $0 | |
| Oct 23, 2025 | Iv, Llc Trv Gp | Executive | Sale | 477,401 | $10.15 | $4.8M | Large |
| Sep 25, 2025 | Iv, Llc Trv Gp | Executive | Sale | 500,000 | $8.02 | $4.0M | Large |
| Sep 16, 2025 | Iv, Llc Trv Gp | Executive | Sale | 363,541 | $7.04 | $2.6M | Large |
| Sep 8, 2025 | Iv, Llc Trv Gp | Executive | Sale | 86,459 | $7.04 | $608.7K | Large |
| Sep 5, 2025 | Iv, Llc Trv Gp | Executive | Sale | 642,906 | $7.00 | $4.5M | Large |
| Aug 22, 2025 | Ventures Gp Iv, L.p. Third Rock | Executive | Sale | 302,194 | $7.00 | $2.1M | Large |
| Aug 19, 2025 | Ventures Gp Iv, L.p. Third Rock | Executive | Sale | 1,100,000 | $7.01 | $7.7M | Large |
| Sep 13, 2024 | Iv, Llc Trv Gp | Executive | Sale | 67,400 | $10.53 | $709.7K | Large |
| Sep 5, 2024 | Iv, Llc Trv Gp | Executive | Sale | 75,000 | $11.56 | $867.0K | Large |
| Aug 30, 2024 | Ventures Iv, L.p. Third Rock | Executive | Sale | 175,000 | $11.60 | $2.0M | Large |
| Aug 27, 2024 | Ventures Iv, L.p. Third Rock | Executive | Sale | 25,000 | $11.55 | $288.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 44 | $59.1M | 71.0% |
Purchase(P) | 12 | $21.6M | 26.0% |
Award(A) | 26 | $2.4M | 2.9% |
Insider selling pressure at Tango Therapeutics, Inc. has increased, with 20 insiders executing 82 transactions across all time. Total sales of $59.1M significantly outpace purchases of $21.6M, resulting in a net outflow of $37.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.